



ANNOUNCEMENT TO THE SINGAPORE EXCHANGE
8 February 2007

LMA RAISES STAKE IN AUSTRALIAN DISTRIBUTOR FROM 30% TO 80%
Addendum to announcement made to the Singapore Exchange on 7 February 2007

Singapore - Mainboard-listed LMA International NV ("LMA"), the global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management devices, announced yesterday that it has agreed to acquire a further 50% in the equity of Australian distributor LMA Pacific Medical Pty Ltd ("LMA PacMed"), increasing its investment from 30% to 80% for a consideration of US\$9.7 million.

Based on the terms of the agreement, 60% of this consideration will be in cash and 40% in new LMA shares to be issued at S\$0.88 per share. The consideration is based on a willing-buyer willing-seller basis and is based on a multiple of LMA PacMed's after tax profit for its financial year ended 30 June 2006. This arrangement is similar to that which was used as a basis for LMA's initial 30% investment in LMA PacMed, announced to the Singapore Exchange on 23 November 2005.

LMA PacMed, a privately owned company based in Melbourne, Australia, is a distributor of LMA's products in Australia and New Zealand, and manages a sales network that distributes LMA's products in Korea and Taiwan.

- Ends -

For media queries, please contact:

Gavin Anderson & Company, Tel: +65 6339 9110
Sharon Seetho, Tel: +65 9009 8495

About LMA

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA-Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Bonn, Germany and San Diego, California. Through its 50 percent joint venture in LMA Urology Limited, the Group has a

subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.